MEASURE: a multi-centre, single-arm, observational, 96 week, phase IV study to evaluate treatment adherence when using RebiSmartTM for self-injection of subcutaneous interferon-β 1a in multi-dose cartridges in subjects with relapsing multiple sclerosis: P920


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles